Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Polish Translation
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, Y.
Right arrow Articles by Iwamoto, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sato, Y.
Right arrow Articles by Iwamoto, J.
Related Collections
Right arrow All Medical/Systemic disease
Right arrow Parkinson's disease/Parkinsonism
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2007;68:911-915
© 2007 American Academy of Neurology

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease

Yoshihiro Sato, MD, Yoshiaki Honda, MD and Jun Iwamoto, MD

From the Department of Neurology (Y.S., Y.H.), Mitate Hospital, Tagawa; and Department of Sport Medicine (J.I.), Keio University School of Medicine, Tokyo, Japan.

Address correspondence and reprint requests to Dr. Yoshihiro Sato, Department of Neurology, Mitate Hospital, 3237 Yugeta, Tagawa 826-0041, Japan; e-mail: y-sato{at}ktarn.or.jp

Background: There is a high incidence of hip fractures in patients with Parkinson disease (PD). Bone mineral density (BMD) is decreased in patients with PD, correlating with the immobilization-induced bone resorption and hypovitaminosis D with compensatory hyperparathyroidism.

Objective: To evaluate the effectiveness of risedronate, an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in elderly men with PD.

Methods: This was a 2-year, randomized, double-blind, placebo-controlled trial. In a prospective study of patients with PD, 121 patients received a daily dose of 2.5 mg risedronate and vitamin D2 1,000 IU for 2 years, and the remaining 121 received placebo and vitamin D2 1,000 IU. Incidence of hip fractures was compared between the two groups.

Results: Nine patients sustained hip fractures in the placebo group, and three hip fractures occurred in the risedronate group. The relative risk of a hip fracture in the risedronate group vs the placebo group was 0.33 (95% CI, 0.09 to 1.20). BMD increased by 2.2% in the risedronate group and decreased by 2.9% in the placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 46.7% in the risedronate group and by 33.0% in the placebo group.

Conclusion: Treatment with risedronate and vitamin D2 increases bone mineral density in elderly men with Parkinson disease and reduces the risk of hip fractures.

Supported by the Takeda Pharmaceutical Co., Ltd., Osaka, Japan.

Disclosure: The authors report no conflicts of interest.

Received May 23, 2006. Accepted in final form November 21, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.